MLC601
1 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
1
Ongoing
0
Recruiting
0
Completed
1
Sites
1
Countries
1
Endpoints
4
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 4 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 2 of 4 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
1
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
1 of 1
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT01696123Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine | MLC601 Alzheimer’s disease | Age ≥50 | Ph 2 | Completed | 1 | Jan 2012 | 1 |
Showing 1-1 of 1 trials